CANAQUEST MEDICAL CORP announced Statistically Significant efficacy results from the Clinical Dose & Efficacy Study ("Study") conducted by Dr. W McIntyre Burnham, emeritus professor of the University of Toronto's Temerty Faculty of Medicine. In comparison to standard CBD, CQ-001 (cannabidiol "CBD" + IP formula - essential fatty acids) demonstrated 40% more seizure reduction at a medium dose in the maximal electroshock seizure (MES) model. This result indicates that CQ-001 is stronger than standard CBD, and could be used a lower dose to achieve seizure control.

Highlights derived from the Study are as follows: The enhanced efficacy from these clinical studies further validates the pre-clinical trial results obtained by Dr. Steven Laviolette, a professor and neuroscientist, at Western University. These results set the stage for substantially smaller dosages of CBD generating the desired results without the negative side effects and will define a dosage of CQ-001 for a clinical trial (Phase II/III, double-blind trial, 60 patients). CanaQuest has identified the regulatory pathways to obtain Rx Drug Identification Numbers (DINs) in Canada and the USA for Epilepsy rare neurological conditions.

CQ-001, in combination with its proprietary processing and delivery method, is estimated to be approved in about 3 years.